MRNA|Moderna Inc|Price:41.010|Chg%:0.14

More Details of Moderna Inc Company

Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. The Company’s diverse development pipeline consists of 44 therapeutic and vaccine programs, 11 of which are in late-stage development. Its commercial products include Spikevax (its COVID vaccine) and mRESVIA (its respiratory syncytial virus (RSV) vaccine). Additionally, it has achieved four positive Phase III data readouts for its COVID vaccine (mRNA-1283), its RSV vaccine for high-risk adults aged 18 to 59 (mRNA-1345), its seasonal flu+COVID vaccine (mRNA-1083), and its seasonal flu vaccine (mRNA-1010).

Moderna Inc Info



Ticker SymbolMRNA

Company nameModerna Inc

IPO dateDec 07, 2018

CEOBancel (Stephane)

Number of employees5800

Security typeOrdinary Share

Fiscal year-endDec 07

Address325 Binney Street

CityCAMBRIDGE

Stock exchangeNASDAQ OMX - NASDAQ BASIC

CountryUnited States of America

Postal code02142

Phone16177146500

Websitehttps://www.modernatx.com/

Ticker SymbolMRNA

IPO dateDec 07, 2018

CEOBancel (Stephane)

Company Executives of Moderna Inc



Name

Name/Position

Position

Shareholding

Change

Dr. Stephen Hoge, M.D.

President

1.61M

+336.00%

Mr. Paul Sagan

Independent Director

494.13K

--

Ms. Shannon Thyme Klinger

Corporate Secretary, Chief Legal Officer

53.23K

+24493.00%

Mr. James M. Mock

Chief Financial Officer

43.87K

+672.00%

Dr. Elizabeth G. (Betsy) Nabel, M.D.

Independent Director

3.08K

--

Tallett (Elizabeth E)

Independent Director

703.00

--

Dr. Francois Nader, M.D.

Independent Director

--

Ms. Tracey Franklin

Chief People and Digital Technology Officer

--

Dr. Sandra J. Horning, M.D.

Independent Director

--

Ms. Kate Cronin

Chief Brand Officer

--

Name

Name/Position

Position

Shareholding

Change

Dr. Stephen Hoge, M.D.

President

1.61M

+336.00%

Mr. Paul Sagan

Independent Director

494.13K

--

Ms. Shannon Thyme Klinger

Corporate Secretary, Chief Legal Officer

53.23K

+24493.00%

Mr. James M. Mock

Chief Financial Officer

43.87K

+672.00%

Dr. Elizabeth G. (Betsy) Nabel, M.D.

Independent Director

3.08K

--

Tallett (Elizabeth E)

Independent Director

703.00

--

Revenue Breakdown

Currency: USDUpdated: Tue, Jan 6

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

Relevant data have not been disclosed by the company yet.

By RegionUSD

Name

Revenue

Proportion

United States

782.00M

80.37%

Rest of the World

175.00M

17.99%

Europe

16.00M

1.64%

By Business

By Region

Relevant data have not been disclosed by the company yet.

Shareholding Stats

Updated: Thu, Feb 5

Shareholders

Shareholder Types

Shareholders

Proportion

The Vanguard Group, Inc.

10.62%

Baillie Gifford & Co.

5.27%

BlackRock Institutional Trust Company, N.A.

5.12%

State Street Investment Management (US)

4.38%

Two Sigma Investments, LP

3.66%

Other

70.95%

Shareholders

Proportion

The Vanguard Group, Inc.

10.62%

Baillie Gifford & Co.

5.27%

BlackRock Institutional Trust Company, N.A.

5.12%

State Street Investment Management (US)

4.38%

Two Sigma Investments, LP

3.66%

Other

70.95%

Shareholder Types

Shareholders

Proportion

Investment Advisor

43.38%

Investment Advisor/Hedge Fund

14.01%

Hedge Fund

9.99%

Corporation

4.63%

Research Firm

4.27%

Individual Investor

2.73%

Bank and Trust

1.88%

Venture Capital

1.20%

Pension Fund

1.04%

Other

16.88%

Institutional Shareholding



Updated: Thu, Jan 1

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q4

1864

297.63M

76.18%

-17.74M

2025Q3

1925

289.85M

74.21%

-20.82M

2025Q2

2015

310.55M

79.82%

-10.63M

2025Q1

2127

325.75M

84.24%

-21.87M

2024Q4

2176

321.41M

83.21%

-6.67M

2024Q3

2154

311.92M

81.18%

-17.40M

2024Q2

2186

316.03M

82.47%

-13.47M

2024Q1

2203

318.24M

83.12%

-1.14M

2023Q4

2309

311.40M

81.63%

+3.41M

2023Q3

2445

301.25M

79.05%

-6.86M

Shareholder Activity



Name

Shares Held

Proportion

Change

Chg %

Date

The Vanguard Group, Inc.

41.10M

10.52%

-518.17K

-1.24%

Sep 30, 2025

Baillie Gifford & Co.

21.85M

5.59%

-247.46K

-1.12%

Sep 30, 2025

BlackRock Institutional Trust Company, N.A.

20.00M

5.12%

+358.11K

+1.82%

Sep 30, 2025

State Street Investment Management (US)

17.11M

4.38%

-162.04K

-0.94%

Sep 30, 2025

Two Sigma Investments, LP

14.30M

3.66%

-472.03K

-3.19%

Sep 30, 2025

Fidelity Management & Research Company LLC

12.28M

3.14%

-7.18M

-36.87%

Sep 30, 2025

Geode Capital Management, L.L.C.

9.25M

2.37%

+372.07K

+4.19%

Sep 30, 2025

Boston Biotech Ventures, L.L.C.

9.21M

2.36%

--

Sep 30, 2025

Theleme Partners LLP

8.07M

2.07%

+200.00K

+2.54%

Sep 30, 2025

Related ETFs



Updated: Sat, Dec 6

Name

Proportion

iShares Genomics Immunology and Healthcare ETF

3.72%

Global X Genomics & Biotechnology ETF

3.52%

First Trust NYSE Arca Biotechnology Index Fund

3.4%

Langar Global HealthTech ETF

3.2%

WisdomTree BioRevolution Fund

2.72%

State Street SPDR S&P Biotech ETF

2.19%

VanEck Biotech ETF

1.82%

Invesco S&P 500 Equal Weight Health Care ETF

1.82%

iShares Health Innovation Active ETF

1.72%

ROBO Global Healthcare Technology & Innovation ETF

1.6%

iShares Genomics Immunology and Healthcare ETF

Proportion3.72%

Global X Genomics & Biotechnology ETF

Proportion3.52%

First Trust NYSE Arca Biotechnology Index Fund

Proportion3.4%

Langar Global HealthTech ETF

Proportion3.2%

WisdomTree BioRevolution Fund

Proportion2.72%

State Street SPDR S&P Biotech ETF

Proportion2.19%

VanEck Biotech ETF

Proportion1.82%

Invesco S&P 500 Equal Weight Health Care ETF

Proportion1.82%

iShares Health Innovation Active ETF

Proportion1.72%

ROBO Global Healthcare Technology & Innovation ETF

Proportion1.6%

Dividend



A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Splits



Date

Ex-dividend Date

Type

Ratio

No Data

Date

Ex-dividend Date

Type

Ratio

No Data